Merck & Co. Inc. Reports Strong Q3 2025 Results Amid Strategic Developments

Merck's net income for Q3 2025 rose to $5.78 billion, substantially up from $3.15 billion reported in Q3 2024. This increase reflects a strong operational performance despite ongoing pricing pressures and significant investments in research and development (R&D).

The income statement for Q3 2025 indicates a notable increase in revenue and a decrease in costs relative to the previous year, leading to improved profitability.

The revenue for the quarter reached $17.27 billion, while costs and expenses totaled $10.76 billion. The operating income stood at $6.50 billion, up from $3.92 billion in the same quarter last year. Research and development expenses, while still substantial at $4.23 billion, showed a decrease from $5.86 billion a year earlier, largely due to lower business development activity.

Merck has engaged in several significant transactions aimed at strengthening its portfolio and enhancing its research capabilities.

In October 2025, Merck announced its acquisition of Verona Pharma plc for approximately $10.5 billion. This strategic acquisition includes Ohtuvayre (ensifentrine), which has been approved in the U.S. for chronic obstructive pulmonary disease (COPD) maintenance treatment. The integration of this asset is expected to drive revenue growth in the coming years.

Also in October, Merck entered into a funding arrangement with Blackstone Life Sciences, securing $700 million to support the development costs for MK-2870 (sacituzumab tirumotecan). This funding will alleviate some of the financial burdens associated with R&D, allowing Merck to invest in other critical areas of its pipeline.

Additionally, Merck reached an agreement with Dr. Falk Pharma GmbH to assume full responsibility for the development of MK-8690, an investigational anti-CD30 ligand monoclonal antibody. Merck will pay Falk $150 million upfront, along with potential milestone payments and royalties, further demonstrating its commitment to expanding its innovative drug portfolio.

Despite its strong financial performance, Merck faces significant challenges, particularly in pricing and tariffs. The company is navigating a complex landscape marked by increased government price-setting and healthcare cost containment efforts. The selection of Januvia for the Drug Price Negotiation Program, with government pricing set to take effect in January 2026, poses a potential threat to future revenues.

In addition to pricing pressures, Merck is contending with tariffs on foreign imports and the implications of proposed executive orders concerning drug pricing policies. These factors may adversely affect Merck's pricing strategies and reimbursement in the U.S. market. In response, Merck has initiated legal action against the U.S. government regarding these pricing policies.

Merck's diverse product portfolio has shown varying performance across different segments:

The oncology franchise continues to be a key growth driver, with Keytruda achieving global sales growth of 10% in Q3 2025, mainly due to increased demand across various cancer indications. Companion products like Welireg and Lynparza also contributed to the segment's overall positive performance.

Conversely, vaccines sales, particularly Gardasil and Gardasil 9, have faced significant declines due to lower demand, particularly in China and Japan. The virology segment also saw reduced sales for Lagevrio, attributed to a decrease in COVID-19 cases.

Merck's animal health segment reported growth in livestock product sales, although companion animal products faced slight declines. The company anticipates a rebound in this segment as veterinary visits stabilize.

Merck's liquidity position remains strong, with cash provided by operating activities totaling $13.6 billion in the first nine months of 2025. However, this figure represents a decrease from $18.0 billion in the same period last year. The company's strategic focus on maintaining a robust balance sheet is evident, with total assets reported at $129.5 billion.

The balance sheet reflects substantial growth, with total equity increasing to $51.90 billion in Q3 2025 from $44.56 billion in Q3 2024. This growth is supported by retained earnings and strategic acquisitions, positioning Merck favorably for future investments and growth opportunities.

Merck & Co. Inc.'s Q3 2025 results highlight a company poised for continued growth despite external challenges. With strategic acquisitions and a diverse product portfolio, Merck is navigating the complexities of the pharmaceutical landscape while addressing critical healthcare needs. As the company moves forward, its ability to adapt to pricing pressures and leverage its innovative pipeline will be crucial for sustaining its upward trajectory.